Advanced search
Publication Cover
Drug Development and Industrial Pharmacy Volume 38, 2012 - Issue 5
Submit an article Journal homepage
338
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Microneedle assisted iontophoretic transdermal delivery of prochlorperazine edisylate

Chandra Sekhar KolliCalifornia Northstate College of Pharmacy, Rancho Cordova, CA, USA
,
Jin XiaoHarrison School of Pharmacy, Auburn University, Auburn, AL, USA
,
Daniel L. ParsonsHarrison School of Pharmacy, Auburn University, Auburn, AL, USA
&
R. Jayachandra BabuHarrison School of Pharmacy, Auburn University, Auburn, AL, USACorrespondence[email protected]
Pages 571-576 | Received 01 Apr 2011, Accepted 23 Aug 2011, Published online: 08 Oct 2011

References

  • Hao Z, Jie Z, James BS. (2002). Oral mucosal drug delivery clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet, 41:661–680.
  • Kwon KT, Rudkin SE, Langdorf MI. (2002). Antiemetic use in pediatric gastroenteritis: A national survey of emergency physicians, pediatricians, and pediatric emergency physicians. Clin Pediatr (Phila), 41:641–652.
  • Obata Y, Otake Y, Takayama K. (2010). Feasibility of transdermal delivery of prochlorperazine. Biol Pharm Bull, 33:1454–1457.
  • Finn A, Collins J, Voyksner R, Lindley C. (2005). Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route. J Clin Pharmacol, 45:1383–1390.
  • Kalia YN, Naik A, Garrison J, Guy RH. (2004). Iontophoretic drug delivery. Adv Drug Deliv Rev, 56:619–658.
  • Patel S, Shukla C, Patel G, Stagni G. (2010). Pharmacokinetics of amitriptyline in rabbit skin and plasma following iontophoretic administrations. Drug Dev Ind Pharm, 36:379–384.
  • Prausnitz MR. (2004). Microneedles for transdermal drug delivery. Adv Drug Deliv Rev, 56:581–587.
  • Banga AK. (2006). New technologies to allow transdermal delivery of therapeutic proteins and small water-soluble drugs. Am J Drug Deliv, 4:221–230.
  • Lanke SS, Kolli CS, Strom JG, Banga AK. (2009). Enhanced transdermal delivery of low molecular weight heparin by barrier perturbation. Int J Pharm, 365:26–33.
  • McAllister DV, Wang PM, Davis SP, Park JH, Canatella PJ, Allen MG et al. (2003). Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci USA, 100:13755–13760.
  • Li G, Badkar A, Nema S, Kolli CS, Banga AK. (2009). In vitro transdermal delivery of therapeutic antibodies using maltose microneedles. Int J Pharm, 368:109–115.
  • Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. (2002). Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med, 8:415–419.
  • Rastogi R, Anand S, Dinda AK, Koul V. (2010). Investigation on the synergistic effect of a combination of chemical enhancers and modulated iontophoresis for transdermal delivery of insulin. Drug Dev Ind Pharm, 36:993–1004.
  • Vemulapalli V, Yang Y, Friden PM, Banga AK. (2008). Synergistic effect of iontophoresis and soluble microneedles for transdermal delivery of methotrexate. J Pharm Pharmacol, 60:27–33.
  • Wu XM, Todo H, Sugibayashi K. (2007). Enhancement of skin permeation of high molecular compounds by a combination of microneedle pretreatment and iontophoresis. J Control Release, 118:189–195.
  • Ward AE. (1988). Studies of prochlorperazine as a buccal tablet (Buccastem) and an oral tablet (Stemetil) for the treatment of dizziness, nausea or vomiting in a general practice setting. Br J Clin Pract, 42:228–232.
  • Taylor WB, Bateman DN. (1987). Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. Br J Clin Pharmacol, 23:137–142.
  • Malone JM Jr, Christensen CW, Yashinsky D, Malviya VK, Deppe G. (1990). Prochlorperazine and transdermal scopolamine added to a metoclopramide antiemetic regimen. A controlled comparison. J Reprod Med, 35:932–934.
  • Kalluri H, Banga AK. (2011). Formation and closure of microchannels in skin following microporation. Pharm Res, 28:82–94.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.